K M Doll1, A C Snavely2, A Kalinowski3, D E Irwin4, J T Bensen2, V Bae-Jump5, J F Boggess5, J T Soper5, W R Brewster5, P A Gehrig5. 1. Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Cancer Care Quality Training Program, Division of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. Electronic address: kmdoll@med.unc.edu. 2. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. 3. Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 4. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. 5. Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Abstract
OBJECTIVE: Quality of life (QoL) for women with gynecologic malignancies is predictive of chemotherapy related toxicity and overall survival but has not been studied in relation to surgical outcomes and hospital readmissions. Our goal was to evaluate the association between baseline, pre-operative QoL measures and 30-day post-operative morbidity and health resource utilization by gynecologic oncology patients. METHODS: We analyzed prospectively collected survey data from an institution-wide cohort study. Patients were enrolled from 8/2012 to 6/2013 and medical record data was abstracted (demographics, comorbid conditions, and operative outcomes). Responses from several validated health-related QoL instruments were collected. Bivariate tests and multivariable linear and logistic regression models were used to evaluate factors associated with QoL scores. RESULTS: Of 182 women with suspected gynecologic malignancies, 152 (84%) were surveyed pre-operatively and 148 (81%) underwent surgery. Uterine (94; 63.5%), ovarian (26; 17.5%), cervical (15; 10%), vulvar/vaginal (8; 5.4%), and other (5; 3.4%) cancers were represented. There were 37 (25%) cases of postoperative morbidity (PM), 18 (12%) unplanned ER visits, 9(6%) unplanned clinic visits, and 17 (11.5%) hospital readmissions (HR) within 30days of surgery. On adjusted analysis, lower functional well-being scores resulted in increased odds of PM (OR 1.07, 95%CI 1.01-.1.21) and HR (OR 1.11, 95%CI 1.03-1.19). A subjective global assessment score was also strongly associated with HR (OR 1.89, 95%CI 1.14, 3.16). CONCLUSION: Lower pre-operative QoL scores are significantly associated with post-operative morbidity and hospital readmission in gynecologic cancer patients. This relationship may be a novel indicator of operative risk.
OBJECTIVE: Quality of life (QoL) for women with gynecologic malignancies is predictive of chemotherapy related toxicity and overall survival but has not been studied in relation to surgical outcomes and hospital readmissions. Our goal was to evaluate the association between baseline, pre-operative QoL measures and 30-day post-operative morbidity and health resource utilization by gynecologic oncology patients. METHODS: We analyzed prospectively collected survey data from an institution-wide cohort study. Patients were enrolled from 8/2012 to 6/2013 and medical record data was abstracted (demographics, comorbid conditions, and operative outcomes). Responses from several validated health-related QoL instruments were collected. Bivariate tests and multivariable linear and logistic regression models were used to evaluate factors associated with QoL scores. RESULTS: Of 182 women with suspected gynecologic malignancies, 152 (84%) were surveyed pre-operatively and 148 (81%) underwent surgery. Uterine (94; 63.5%), ovarian (26; 17.5%), cervical (15; 10%), vulvar/vaginal (8; 5.4%), and other (5; 3.4%) cancers were represented. There were 37 (25%) cases of postoperative morbidity (PM), 18 (12%) unplanned ER visits, 9(6%) unplanned clinic visits, and 17 (11.5%) hospital readmissions (HR) within 30days of surgery. On adjusted analysis, lower functional well-being scores resulted in increased odds of PM (OR 1.07, 95%CI 1.01-.1.21) and HR (OR 1.11, 95%CI 1.03-1.19). A subjective global assessment score was also strongly associated with HR (OR 1.89, 95%CI 1.14, 3.16). CONCLUSION: Lower pre-operative QoL scores are significantly associated with post-operative morbidity and hospital readmission in gynecologic cancerpatients. This relationship may be a novel indicator of operative risk.
Authors: Brian Badgwell; Jordan Stanley; George J Chang; Matthew H G Katz; Heather Y Lin; Jing Ning; Suzanne V Klimberg; Janice N Cormier Journal: J Surg Oncol Date: 2013-06-26 Impact factor: 3.454
Authors: Jason D Wright; Thomas J Herzog; Alfred I Neugut; William M Burke; Yu-Shiang Lu; Sharyn N Lewin; Dawn L Hershman Journal: Gynecol Oncol Date: 2012-06-24 Impact factor: 5.482
Authors: Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Frasure; Deborah K Armstrong; Lari B Wenzel Journal: Gynecol Oncol Date: 2011-11-23 Impact factor: 5.482
Authors: Jason D Wright; Thomas J Herzog; Alfred I Neugut; William M Burke; Yu-Shiang Lu; Sharyn N Lewin; Dawn L Hershman Journal: Obstet Gynecol Date: 2012-10 Impact factor: 7.661
Authors: Rachel M Clark; Whitfield B Growdon; Andrew Wiechert; David Boruta; Marcela Del Carmen; Anne Kathryn Goodman; Leslie Bradford; Alejandro Rauh-Hain; John O Schorge Journal: Gynecol Oncol Date: 2013-06-05 Impact factor: 5.482
Authors: Chukwuemeka U Ihemelandu; Richard McQuellon; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine Journal: Ann Surg Oncol Date: 2013-06-08 Impact factor: 5.344
Authors: Michael J Englesbe; Michael N Terjimanian; Jay S Lee; Kyle H Sheetz; Calista M Harbaugh; Adnan Hussain; Sven A Holcombe; June Sullivan; Darrell A Campbell; Stewart C Wang; Christopher J Sonnenday Journal: J Am Coll Surg Date: 2013-03-21 Impact factor: 6.113
Authors: Larissa A Meyer; Alpa M Nick; Qiuling Shi; Xin Shelley Wang; Loretta Williams; Tremaine Brock; Maria D Iniesta; Kelly Rangel; Karen H Lu; Pedro T Ramirez Journal: Gynecol Oncol Date: 2015-01-31 Impact factor: 5.482
Authors: Kemi M Doll; Alison K Kalinowski; Anna C Snavely; Debra E Irwin; Jeannette T Bensen; Victoria L Bae-Jump; Kenneth H Kim; Linda Van Le; Daniel L Clarke-Pearson; Paola A Gehrig Journal: Cancer Date: 2014-09-23 Impact factor: 6.860
Authors: Rebecca S Lash; Janice F Bell; Sarah C Reed; Hermine Poghosyan; James Rodgers; Katherine K Kim; Richard J Bold; Jill G Joseph Journal: Cancer Nurs Date: 2017 Mar/Apr Impact factor: 2.592
Authors: C Emi Bretschneider; Kemi M Doll; Jeannette T Bensen; Paola A Gehrig; Jennifer M Wu; Elizabeth J Geller Journal: Int Urogynecol J Date: 2016-02-12 Impact factor: 2.894
Authors: Janae L Kirsch; Michael E Robinson; Christina S McCrae; Elizabeth L Kacel; Shan S Wong; Seema Patidar; Timothy S Sannes; Stephanie Garey; Jacqueline C Castagno; Deidre B Pereira Journal: Pain Med Date: 2020-01-01 Impact factor: 3.750
Authors: Kemi M Doll; Emma L Barber; Jeannette T Bensen; Matthew C Revilla; Anna C Snavely; Antonia V Bennett; Bryce B Reeve; Paola A Gehrig Journal: Am J Obstet Gynecol Date: 2016-04-27 Impact factor: 8.661